VIP and Parkinson disease: Although selective VIP receptor agonists have not yet been tested in clinical cohorts of PD patients, further investigation is merited as VIP has been shown to shift systemic immunity towards a less reactive and more anti-inflammatory phenotype in animal models of PD.